Review
Status quo, policy review and prospect of stem cell clinical trials in China
Xiang Nan, Wang Guosheng, Li Xiaomei
Published 2020-10-01
Cite as Chin J Cell Stem Cell (Electronic Edition), 2020,10(05): 303-309. DOI: 10.3877/cma.j.issn.2095-1221.2020.05.009
Abstract
Stem cell research is a hot and cutting-edge topic in biomedical research in recent years. With self-renewal and multi-directional differentiation as the biological characteristics of stem cells, stem cell therapy has made significant progress in the treatment of cardiovascular diseases, bone and joint diseases, autoimmune diseases and has attracted worldwide attention. At present, the application of stem cell is still in clinical trials in China. With the introduction of policies relevant to the research into clinical applications of stem cells, fast progress has been made in clinical trials with stem cells in China. This article analyzes the current status of stem cell clinical research in China, reviews the development of supervision policies in relation to stem cell research, and discusses the problems existing in the supervision and ethics of stem cell clinical research, in an attempt to provide a reference for the further development of stem cell clinical trials in China.
Key words:
Stem cells; Clinical research; Policy
Contributor Information
Xiang Nan
Department of Rheumatology and Immunology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Wang Guosheng
Department of Rheumatology and Immunology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Li Xiaomei
Department of Rheumatology and Immunology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
